Abstract
Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Current Drug Delivery
Title:New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis
Volume: 11 Issue: 2
Author(s): V. Dinesh Kumar, Priya Ranjan Prasad Verma and Sandeep Kumar Singh
Affiliation:
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Abstract: Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Export Options
About this article
Cite this article as:
Kumar Dinesh V., Verma Ranjan Prasad Priya and Singh Kumar Sandeep, New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/15672018113106660057
DOI https://dx.doi.org/10.2174/15672018113106660057 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Exploring Protein-Protein and Protein-Ligand Interactions in the Immune System using Molecular Dynamics and Continuum Electrostatics
Current Physical Chemistry Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology The Epigenetics of Breast Carcinogenesis and Metastasis
Current Genomics The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Innate and Adaptive Immune Responses in Allergic Contact Dermatitis and Autoimmune Skin Diseases
Inflammation & Allergy - Drug Targets (Discontinued) HIV-1 Protease Inhibitors: A Comparative QSAR Analysis
Current Medicinal Chemistry Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry